e-SPACE Cardio-Renal-Metabolic 2022: On-demand

Published: 11 April 2022

  • Views:

    Views Icon 17588
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

e-SPACE CARDIO-RENAL-METABOLIC 2022, held on 4-6 March 2022, was the second edition of the global online conference on cardio renal metabolic diseases.

 

The organisers, under the direction of a world-renowned scientific committee, brought together leading experts in cardiology, nephrology, and diabetology to share clinical practice strategies in treating the inter-related diseases now affecting hundreds of millions people worldwide.

 

This on-demand version of the event comprises:

 

  • Presentations and discussions with leading experts
  • Evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity
  • Insight to SLGT2i, GLP-1RA and other emerging therapies
  • 'Meet the Expert' sessions

 

e-SPACE Cardio-Renal-Metabolic 2022 was supported by the following companies:

More from this programme

Part 1

Meet the Expert: IgA nephropathy: current optimal management

Part 3

Industry Session: Iron deficiency in heart failure and kidney disease: interdisciplinary crosstalk

Part 5

Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes

Part 7

Meet the Experts: The meaning of Hemoglobin A1C for the nephrologist and the cardiologist

Part 12

Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM

Part 14

Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group

Part 17

Meet the Expert: HIF PHI: What do we know and don't know in 2022

Part 19

Industry Session: SGLT2 inhibition in the comorbid CKD patient

Satellite Symposium supported by an unrestricted educational grant from AstraZeneca

Part 21

Meet the Expert: SGLT2 inhibitors in heart failure: Improving outcomes across the spectrum of the disease

Part 23

Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist

Part 25

Meet the Experts: Personalized care of patients with heart failure: hyperkalemia as a barrier to optimal medical therapy

Part 26

Meet the Expert: SGLT2, the statin of the 21st century

Part 28

Meet the Experts: Reducing the risk of cardiovascular events for patients with CKD and T2DM: new treatment options

Part 31

Meet the Expert: Management of worsening HF

Part 32

Session 16: Harmonising the gluco-and cardio-centric management of diabetes

Faculty Biographies

Vijay Chopra

Vijay Chopra

Senior Director of Clinical Cardiology, Heart Failure and Research

Dr Vijay Chopra is the Senior Director of Clinical Cardiology, Heart Failure and Research in the Heart Failure Programme at the Max Super Specialty Hospital in Saket, New Delhi, India. He is considered a pioneer in preventive cardiology, and has worked extensively in the management of patients with advanced heart disease. He has been principal investigator of numerous international clinical trials. 

Dr Chopra's research interests include preventive cardiology, heart failures and advanced heart diseases. He was awarded the Kutumbiah Prize in Clinical Medicine from CMC Vellore in 1972. He founded the Heart Failure Association of India (HFAI), and served as its first president from 2014 - 2019. 

Dr Chopra has over 50 publications in peer-reviewed journals. 

Dr Vijay Chopra is an Editorial Board member of Cardiac Failure Review and may be contacted

View full profile
Marco Metra

Marco Metra

Professor

Marco Metra is Full Professor of Cardiology and Director of the Institute of Cardiology of the Civil Hospital and University of Brescia, Italy, and Editor-in-Chief of the European Journal of Heart Failure and Senior Consulting Editor of the European Heart Journal.

Prof Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with heart failure. His research is focused on heart failure with, as main areas of interest, β-blocker therapy and, more recently, the assessment and treatment of the patients with acute heart failure.

He has co-chaired with Prof. Teerlink, San Francisco, CA, the phase IIB Pre-RELAX-AHF and the phase III RELAX-AHF randomized placebo controlled trials in patients with acute heart failure and is chairing the current RELAX-AHF-2 trial, which has as primary end-points the effects of serelaxin on the 180-days mortality and on in-hospital worsening heart…

View full profile